Universitätsklinikum Hamburg-Eppendorf

At Universitätsklinikum Hamburg-Eppendorf the pediatric department investigates severe heart emergencies, focusing on cardiogenic shock caused by acute coronary syndrome, sepsis, or decompensated heart failure. The trials seek to determine the safety and potential benefit of new therapies in critical cardiovascular care.

• Evaluation of novel cardioprotective agents
• Assessment of hemodynamic stability in acute settings
• Improving outcomes for patients with severe shock

Two investigator‑led studies are currently active, reflecting the site’s non‑commercial focus on advancing life‑saving treatments for children with life‑threatening cardiac conditions.

The clinic’s research program also targets rare neurodegenerative disorders, specifically the ocular manifestations of neuronal ceroid lipofuscinosis type 2 (CLN2). A key trial evaluates the safety and tolerability of the investigational agent TTX‑381 over an extended follow‑up period, aiming to preserve vision and improve quality of life for affected children.

• Safety profiling of innovative therapies for CLN2
• Long‑term tolerability in pediatric neurodegenerative disease
• Vision preservation strategies in lysosomal storage disorders

With two active studies and a dedicated team of investigators, the department emphasizes compassionate, cutting‑edge research to address unmet needs in pediatric neurology.